Patient characteristics
| . | Steroid-resistant GVHD . | P . | |
|---|---|---|---|
| No (n = 23) . | Yes (n = 25) . | ||
| Median age at treatment, y (range) | 45 (22–56) | 48 (24–62) | .268* |
| Sex of recipient (female/male) | 11/12 | 11/14 | 1.000† |
| Donor | |||
| RD | 14 | 10 | .459† |
| MUD | 5 | 4 | .729† |
| MMUD | 4 | 11 | .232† |
| Sex of donor (female/male) | 5/18 | 12/13 | .256† |
| Sex mismatch R/D | 10 | 11 | 1.000† |
| Disease | |||
| AML, MDS | 7 | 12 | .586† |
| CML | 2 | 1 | .609† |
| ALL | 3 | 3 | 1.000† |
| Lymphoma, CLL | 5 | 4 | .729† |
| MM, amyloidosis | 6 | 5 | .748† |
| Disease score | |||
| 0 | 8 | 13 | .599† |
| 1 | 13 | 6 | .176† |
| 2 | 2 | 6 | .276† |
| ATG | 7 | 13 | .424† |
| Stem cell source (BM/PBSCs) | 1/22 | 1/24 | 1.000† |
| Conditioning | |||
| RIC | 13 | 16 | .817† |
| MAC | 10 | 9 | .790† |
| GVHD site | |||
| Gut only | 13 | 15 | 1.000† |
| Liver only | 10 | 2 | .048† |
| Gut and liver | 0 | 8 | .015† |
| Skin | 11 | 15 | .807† |
| GVHD type | |||
| Classic acute | 11 | 16 | .632† |
| Recurrent acute | 0 | 5 | .061† |
| Late-onset acute | 0 | 3 | .242† |
| Classic chronic | 4 | 0 | .111† |
| Overlap syndrome | 8 | 1 | .031† |
| GVHD prophylaxis | |||
| CsA | 22 | 23 | 1.000† |
| Tacrolimus | 1 | 1 | 1.000† |
| MMF (in combination) | 10 | 12 | 1.000† |
| MTX (in combination) | 9 | 9 | 1.000† |
| Cause of death | |||
| NRM | 1 | 17 | .001† |
| PD | 1 | 2 | 1.000† |
| . | Steroid-resistant GVHD . | P . | |
|---|---|---|---|
| No (n = 23) . | Yes (n = 25) . | ||
| Median age at treatment, y (range) | 45 (22–56) | 48 (24–62) | .268* |
| Sex of recipient (female/male) | 11/12 | 11/14 | 1.000† |
| Donor | |||
| RD | 14 | 10 | .459† |
| MUD | 5 | 4 | .729† |
| MMUD | 4 | 11 | .232† |
| Sex of donor (female/male) | 5/18 | 12/13 | .256† |
| Sex mismatch R/D | 10 | 11 | 1.000† |
| Disease | |||
| AML, MDS | 7 | 12 | .586† |
| CML | 2 | 1 | .609† |
| ALL | 3 | 3 | 1.000† |
| Lymphoma, CLL | 5 | 4 | .729† |
| MM, amyloidosis | 6 | 5 | .748† |
| Disease score | |||
| 0 | 8 | 13 | .599† |
| 1 | 13 | 6 | .176† |
| 2 | 2 | 6 | .276† |
| ATG | 7 | 13 | .424† |
| Stem cell source (BM/PBSCs) | 1/22 | 1/24 | 1.000† |
| Conditioning | |||
| RIC | 13 | 16 | .817† |
| MAC | 10 | 9 | .790† |
| GVHD site | |||
| Gut only | 13 | 15 | 1.000† |
| Liver only | 10 | 2 | .048† |
| Gut and liver | 0 | 8 | .015† |
| Skin | 11 | 15 | .807† |
| GVHD type | |||
| Classic acute | 11 | 16 | .632† |
| Recurrent acute | 0 | 5 | .061† |
| Late-onset acute | 0 | 3 | .242† |
| Classic chronic | 4 | 0 | .111† |
| Overlap syndrome | 8 | 1 | .031† |
| GVHD prophylaxis | |||
| CsA | 22 | 23 | 1.000† |
| Tacrolimus | 1 | 1 | 1.000† |
| MMF (in combination) | 10 | 12 | 1.000† |
| MTX (in combination) | 9 | 9 | 1.000† |
| Cause of death | |||
| NRM | 1 | 17 | .001† |
| PD | 1 | 2 | 1.000† |
R/D indicates recipient/donor; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; ALL, acute lymphoid leukemia; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; BM, bone marrow; PBSCs, peripheral blood stem cells; PD, progressive disease; CsA, cyclosporine A; MMF, mycofenolate mofetil; and MTX, methotrexate.
Mann-Whitney test.
Fisher exact test (2-tailed).